Physician profile
Chris Simpson
NPI 1023496247
$6,195.63
in general payments reported to CMS, 2019-2025
28 companies · $786 in 2025
The $786 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $788 · 2020: $375 · 2021: $725 · 2022: $1,087 · 2023: $981 · 2024: $1,453 · 2025: $786.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,220.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,219.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,491.52 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $591.69 | 2022-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $531.03 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Amgen INC. | $325.32 | 2019-2025 | Krystexxa, Repatha, Otezla |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $294.40 | 2024-2025 | Caplyta |
| Lilly USA, LLC | $259.13 | 2020-2025 | Mounjaro, Zepbound |
| Abbott Laboratories | $207.05 | 2022-2025 | Freestyle Libre 3 |
| Nevro Corp. | $192.00 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $177.54 | 2022-2023 | |
| Antares Pharma, INC. | $168.99 | 2022-2025 | Xyosted |
| Glaxosmithkline, LLC. | $153.06 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Verity Pharmaceuticals INC. | $110.25 | 2024-2025 | Tlando |
| Biohaven Pharmaceutical Holding Company LTD. | $102.81 | 2022 | |
| Corcept Therapeutics | $88.87 | 2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.74 | 2019-2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $69.28 | 2023-2024 | |
| Exact Sciences Corporation | $60.09 | 2023-2025 | Cologuard Collection Kit |
| Currax Pharmaceuticals LLC | $46.88 | 2022-2024 | Contrave |
| Merck Sharp & Dohme LLC | $39.83 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $35.37 | 2024-2025 | Quviviq, Quviviq |
| Tolmar, INC. | $34.68 | 2025 | Jatenzo |
| Takeda Pharmaceuticals U.S.A., INC. | $28.72 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $21.00 | 2024 | Rexulti |
| Esperion Therapeutics, INC. | $20.19 | 2025 | Nexletol |
| Sanofi Pasteur INC. | $20.16 | 2019 | |
| Tris Pharma INC | $15.63 | 2024 | Dyanavel Xr |
| Phadia US INC. | $15.14 | 2024 | Immunocap |
| Allergan, INC. | $14.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chris Simpson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.